Most published studies on GLP-1 medications have focused on individuals with concurrent obesity, and evidence in normal-weight individuals with BED is limited
GLP-1 medications such as Tirzepatide and Semaglutide work by reducing appetite, controlling cravings, improving fullness, and helping the body use energy more efficiently leading to steady, sustainable fat loss without restrictive diets or surgery
Furthermore, acute lipid challenges in Gipr BAT / mice fed a high-fat diet for 810 weeks housed at room temperature reveal significantly increased TG excursion, an effect lost upon 28 weeks of high-fat feeding (Beaudry et al., 2019)
Reduced SIRT1 activity correlates with mtDNA damage, mitochondrial fragmentation, decreased membrane potential, and impaired adenosine triphosphate synthesis, all contributing to disease progression and transition to MASH
For example, 1 year of interrupted use fostered a 12% higher risk and 2 years of interrupted use yielded a 16% increased risk